37 Infantile allergy and milk-specific antibodies in breast milk

SUMMAYWe studied the relationship between IgA anti–campylobacter flagellin antibodies in breast milk samples and protection of breastfed infants living in a rural Mexican village from campylobacter infection. There were fewer episodes of campylobacter infection (symptomatic and asymptomatic combined) in infants breastfed with milk containing specific anti-flagellin antibodies (1.2/child/year, 95% CI 0.6–1.8) versus non–breastfed children (3.3/child/year, 95% CI 1.8–4.8; P < 0.01). Infants breastfed with milk that was antiflagellin antibody negative by ELISA also had fewer episodes of infection compared with non-breastfed children, but the difference did not reach statistical significance (1.8/child/year, 95% CI 0.7–3.0 versus 3.3/child/year, 95% CI 1.8–4.8, P > 0.05). Breastfeeding has a protective effect against campylobacter infection and is associated with the presence of specific antibodies directed against campylobacter flagellin.

Download Full-text

The Epithelial Mucin (MUC1) and Virus-Specific Antibodies Target Cell-Free Human Immunodeficiency Virus in Human Breast Milk

The Pediatric Infectious Disease Journal ◽

10.1097/inf.0b013e3181b4151b ◽

2009 ◽

Vol 28 (10) ◽

pp. 932 ◽

Cited By ~ 1

Author(s):

Sujoy Khan

Keyword(s):

Human Immunodeficiency Virus ◽

Breast Milk ◽

Target Cell ◽

Human Breast Milk ◽

Human Breast ◽

Specific Antibodies ◽

Immunodeficiency Virus

Download Full-text

Breast Milk from Immune Thrombocytopenic Mothers Can Contain Anti Platelet Antibodies That Are Associated with Persistent Thrombocytopenia in Neonates

Blood ◽

10.1182/blood.v124.21.4181.4181 ◽

2014 ◽

Vol 124 (21) ◽

pp. 4181-4181 ◽

Cited By ~ 1

Author(s):

Nehama Sharon ◽

Nurit Rosenberg ◽

Uri Seligsohn ◽

Aryeh Simmonds ◽

Yakov Shiff ◽

...

Keyword(s):

Breast Milk ◽

Cultured Cells ◽

Conflicts Of Interest ◽

Common Mechanism ◽

Specific Antibodies ◽

Healthy Women ◽

Fibrinogen Receptor ◽

Platelet Antibodies ◽

History Of ◽

Neonatal Thrombocytopenia

Abstract Purpose: Maternal immune thrombocytopenic purpura (ITP) accounts for 5% of all cases of pregnancy associated thrombocytopenia and is a common cause of neonatal thrombocytopenia. One of the common mechanism involves transfer of IgG autoantibodies against platelet receptors which are found in the blood samples of affected patients. The neonatal thrombocytopenia usually subsides within 2 months. The autoantibodies are often of the IgG type and therefore can cross the placenta and cause fetal and/or neonatal thrombocytopenia. Recently we observed persistence of neonatal ITP which disappeared following discontinuation of breast feeding. The aim of our current work was to discern whether breast milk of mothers with ITP contains anti-platelet antibodies and whether these antibodies may be the cause for persistent neonatal ITP. Methods: Breast milk samples were collected from 12 women with ITP. Six of them were thrombocytopenic during pregnancy and their neonates also had thrombocytopenia. The remaining 6 mothers had a history of ITP but not during the current pregnancy, and neither did their neonates. As controls, breast milk from 8 healthy women was also examinied. The presence of anti-platelet antibodies were evaluated by incubating washed platelets from healthy donors with breast milk or extracted milk – Ig. The type of immune globulin was defined by flow cytometry using fluorescence conjugated anti-human IgA, IgG or total Ig antibodies. To prove that the antibodies were against an antigen that is platelet specific and not against HLA epitopes, we also tested the samples on cultured cells expressing the fibrinogen receptor, αIIbβ3, and compared the results to mock cells (transfected with empty vectors). Results: In the cases of women with active ITP, 3 were positive for anti-platelet antibodies, 2 were inconclusive and one was negative. In the mothers with a history of ITP, 1 was positive, 1 was inconclusive and 4 were negative. No anti-platelet antibodies were found in breast milk of healthy women. In all 6 cases of active ITP, the cell cultured assay for the fibrinogen receptor αIIbβ3 was positive, indicating that there were anti platelet specific antibodies in their milk. Of the 6 neonates of mothers with active ITP, 4 of them required treatment with oral steroids, and the average time to resolution of thrombocytopenia was 3.5 months. Conclusion: This study demonstrates that breastmilk of women with active ITP contains anti platelet specific antibodies. The presence of these antibodies demonstrated an association with persistant and prolonged neonatal thrombocytopenia. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Quantification and progress over time of specific antibodies against SARS-CoV-2 in breast milk of lactating women vaccinated with BNT162b2 Pfizer-BioNTech COVID-19 vaccine (LacCOVID)

10.1101/2021.11.11.21266119 ◽

2021 ◽

Author(s):

Erika Esteve-Palau ◽

Araceli Gonzalez-Cuevas ◽

M. Eugenia Guerrero ◽

Clara Garcia-Terol ◽

M. Carmen Alvarez ◽

...

Keyword(s):

Breast Milk ◽

Pearson Correlation ◽

Vaccination Campaign ◽

Urban Hospital ◽

Lactating Women ◽

Specific Antibodies ◽

Positive Correlation ◽

Time Points ◽

Antibody Levels ◽

Over Time

Importance: To our knowledge, this is the first study to analyze long–term passage (6 months after immunization) of specific antibodies induced by BNT162b2 COVID–19 vaccine through breast milk. Objectives: Main objective: to determine SARS–CoV–2 vaccine induced antibody levels in the breast milk of lactating women 4 weeks after mRNA BNT162b2 Pfizer–BioNTech COVID–19 complete vaccination. Secondary objectives: to analyze SARS–CoV–2 antibody levels (breast milk and serum) at different time–points after vaccination, examine the correlation of SARS–CoV–2 antibody levels between serum and breast milk, describe adverse events related to vaccination (AErV) in both mothers and infants and determine the rate of COVID–19 infections. Design: Prospective cohort study between February and September 2021. Setting: Parc Sanitari Sant Joan de Deu, an urban hospital in Spain. Participants: During our health worker vaccination campaign at our hospital between January and March 2, we recruited 33 lactating women vaccinated with BNT162b2 Pfizer–BioNTech COVID–19. Results: A total of 33 volunteers were included in the study. The median (IQR) age of mothers was 38 (36–39) years and 15 (10–22) months for the infants. Primary end–point: at 4 w after second dose median (IQR) IgG–S1 levels for serum–milk pairs were 12,478 (6,870–20,801) to 50.4 (24.3–104) arbitrary units (AU) per mL. Secondary end–points: SARS–CoV–2 antibody levels at different time–points were (serum–milk): 519 (234–937) to 1 (0–2.9) AU/mL at 2w after first dose, 18,644 (9,923–29,264) to 78 (33.7–128) AU/mL at 2w, 4,094 (2,413–8,480) to 19.9 (10.8–51.9) AU/mL at 12w, and 1,350 (831–2,298) to 8.9 (7.8–31.5) at 24w after second dose. We found a positive correlation of SARS–CoV–2 antibody levels between serum and breast milk (Pearson correlation coefficient 0.68). No serious AErV were observed. We found two (6%) COVID–19 vaccine breakthrough infections. Conclusions: Pfizer–BioNTech COVID–19 vaccination is safe during breastfeeding and it transmits antibodies into breast milk with a positive correlation with serum levels, and both decrease over time in a 6–month follow–up. Infants of breastfeeding vaccinated women could be protected for at least six months after vaccination and serum determination of SARS–CoV–2 IgG–S1 could indicate the breastmilk levels of antibodies during this period.

Download Full-text